Citadel Advisors
TEVA icon

Citadel Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Citadel Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.2M Buy
1,932,400
+178,500
+10% +$5.74M 0.01% 1221
2025
Q4 		$54.7M Buy
1,753,900
+239,800
+16% +$5.91M 0.01% 1330
2025
Q3 		$30.6M Buy
1,514,100
+215,800
+17% +$3.79M ﹤0.01% 1855
2025
Q2 		$21.8M Buy
1,298,300
+166,900
+15% +$2.69M ﹤0.01% 2039
2025
Q1 		$17.4M Sell
1,131,400
-2,783,000
-71% -$49.7M ﹤0.01% 2194
2024
Q4 		$86.3M Buy
3,914,400
+1,605,200
+70% +$29.2M 0.01% 832
2024
Q3 		$41.6M Sell
2,309,200
-1,647,500
-42% -$28.8M 0.01% 1387
2024
Q2 		$64.3M Buy
3,956,700
+2,190,500
+124% +$33.7M 0.01% 955
2024
Q1 		$24.9M Buy
1,766,200
+779,100
+79% +$9.82M ﹤0.01% 1852
2023
Q4 		$10.3M Sell
987,100
-160,200
-14% -$1.5M ﹤0.01% 2800
2023
Q3 		$11.7M Buy
1,147,300
+143,800
+14% +$1.34M ﹤0.01% 2483
2023
Q2 		$7.56M Buy
1,003,500
+394,000
+65% +$3.19M ﹤0.01% 3049
2023
Q1 		$5.39M Sell
609,500
-1,566,700
-72% -$15.5M ﹤0.01% 3685
2022
Q4 		$19.8M Sell
2,176,200
-334,600
-13% -$2.92M ﹤0.01% 1974
2022
Q3 		$20.3M Sell
2,510,800
-2,703,800
-52% -$23.9M ﹤0.01% 1864
2022
Q2 		$39.2M Buy
5,214,600
+3,372,600
+183% +$29.4M 0.01% 1213
2022
Q1 		$17.3M Buy
1,842,000
+483,300
+36% +$4.03M ﹤0.01% 2158
2021
Q4 		$10.9M Sell
1,358,700
-628,000
-32% -$5.67M ﹤0.01% 2931
2021
Q3 		$19.4M Buy
1,986,700
+496,900
+33% +$4.65M ﹤0.01% 2038
2021
Q2 		$14.7M Buy
1,489,800
+222,600
+18% +$2.36M ﹤0.01% 2500
2021
Q1 		$14.6M Sell
1,267,200
-464,200
-27% -$5.32M ﹤0.01% 2403
2020
Q4 		$16.7M Sell
1,731,400
-66,200
-4% -$634K ﹤0.01% 2005
2020
Q3 		$16.2M Sell
1,797,600
-640,100
-26% -$6.77M ﹤0.01% 1759
2020
Q2 		$30.1M Sell
2,437,700
-609,300
-20% -$6.89M 0.01% 1170
2020
Q1 		$27.4M Sell
3,047,000
-555,400
-15% -$5.69M 0.01% 992
2019
Q4 		$35.3M Sell
3,602,400
-238,800
-6% -$2.13M 0.02% 1003
2019
Q3 		$26.4M Buy
3,841,200
+1,169,600
+44% +$8.96M 0.01% 1238
2019
Q2 		$24.7M Buy
2,671,600
+1,490,700
+126% +$18M 0.01% 1235
2019
Q1 		$18.5M Sell
1,180,900
-1,342,600
-53% -$23.7M 0.01% 1408
2018
Q4 		$38.9M Sell
2,523,500
-249,300
-9% -$5.11M 0.02% 760
2018
Q3 		$59.7M Sell
2,772,800
-302,100
-10% -$7.01M 0.03% 656
2018
Q2 		$74.8M Buy
3,074,900
+836,700
+37% +$17.1M 0.04% 494
2018
Q1 		$38.3M Sell
2,238,200
-435,600
-16% -$8.51M 0.02% 728
2017
Q4 		$50.7M Buy
2,673,800
+1,186,600
+80% +$17.9M 0.03% 604
2017
Q3 		$26.2M Buy
1,487,200
+239,700
+19% +$5.39M 0.02% 906
2017
Q2 		$41.4M Buy
1,247,500
+496,500
+66% +$15.4M 0.04% 585
2017
Q1 		$24.1M Buy
751,000
+351,800
+88% +$12M 0.02% 833
2016
Q4 		$14.5M Sell
399,200
-90,400
-18% -$3.61M 0.01% 1090
2016
Q3 		$22.5M Buy
489,600
+116,300
+31% +$6.07M 0.02% 799
2016
Q2 		$18.8M Buy
+373,300
New +$19.9M 0.02% 826

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TEVA Position: Q1 2026 in Review

Citadel Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 3,847,855 shares — an estimated $124M sold.

Citadel Advisors first reported a position in TEVA in Q2 2013 and held it in 51 quarters. The position peaked at $121M in Q4 2023. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Citadel Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 3,847,855 Teva Pharmaceuticals shares in Q1 2026, an estimated $124M.
  • Citadel Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 51 quarters.
  • Citadel Advisors's Teva Pharmaceuticals position peaked at $121M in Q4 2023.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.